In an article that was just published in Proceedings of the National Academy of Sciences (PNAS) by the group of Dr. Manel Esteller, is solved this mystery by describing that in cancer cells the protein that generates the nucleotide "Y" is epigenetically inactivated, causing small but highly aggressive tumors.

The Myelodysplastic Syndromes Group participates in an international study, published in Nature Medicine journal, that confirms for the first time that mutation of the two TP53 gene’s copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population.

Researchers at the Josep Carreras Leukaemia Research Institute have identified a new mechanism for the regulation of the response to metabolic stress that opens the door to new therapeutic targets in the treatment of leukaemia and other malignant haemopathies.

The researcher Manel Esteller, director of the Josep Carreras Leukaemia Research Institute, and leader in Cancer Epigenetics, has been awarded the Narcís Monturiol Medal for scientific and technological merit from the Government of Catalonia.

This spin-off, called OneChain Immunotherapeutics (OCI), was founded by the Josep Carreras Leukaemia Research Institute, ICREA, and Dr. Pablo Menéndez in Barcelona in June 2020.

Francesc Solé, leader of the Myelodysplastic Syndromes group and Blanca Xicoy, leader of the Myeloid Neoplasms group, both from the Josep Carreras Leukaemia Research Institute, collaborate in an article published in Leukemia on the classification and prognosis of Secondary Myelodysplastic Syndromes. 

The researcher Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, and leader in Cancer Epigenetics, is recognized as the most influential biomedical researcher working and living in Spain.

Head of the Carreras Leukemia Center at Marburg University Hospital and vice-president of the José Carreras Leukämie Stiftung, Professor Dr. Andreas Neubauer, leads a trial with ruxolitinib on a COVID-19 patient with success and plans scientific study on the use of an immune inhibitor against this viral disease.

Researchers from the MDS Group of the Josep Carreras Leukaemia Research Institute and the Munich Leukemia Laboratory map the mutations that can ease and accelerate the diagnosis of Myelodysplastic/Myeloproliferative Neoplasms rare malignancies.

PROTEOBLOOD, a French-Spanish cooperative network for the analysis of proteinopathies and the development of individualized therapies in hematological cancers, begins thanks to the cofounding of Interreg POCTEFA.